SmithKline Beecham clinical trials
Acquired by GlaxoSmithKline, Dec 27, 2000 · source ↗
The registry lists 3 studies whose lead sponsor is SmithKline Beecham. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 20, 2013.
- 3studies on the registry
- 0open to participants now
Before and after it joined GlaxoSmithKline
- First submitted before SmithKline Beecham became part of GlaxoSmithKline
- 3
- First submitted after SmithKline Beecham became part of GlaxoSmithKline
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
What it is testing
The drugs SmithKline Beecham’s studies test, most studies first; none is open now — 4 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
- Albendazole1 in phase 30 open · 1
- 0 open · 1
- 0 open · 1
- 0 open · 1
All 3 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Completed267%
- Status unknown or other133%
Registry sponsor names on this page
- SmithKline Beecham3 studies
Something wrong with this grouping? Tell us on the GlaxoSmithKline page.
Studies
Recruiting first, then most recently updated. Showing 3 of 3. All GlaxoSmithKline studies →
- Sequential Chemotherapy in Treating Patients With Residual Disease Following Surgery for Stage IIB, Stage III, or Stage IV Ovarian CancerStatus unknownNCT00003733Phase 2
Sponsor listed in the registry: SmithKline Beecham · First submitted before SmithKline Beecham became part of GlaxoSmithKline
- A Double-Blind, Placebo-Controlled Trial of Albendazole in HIV-Positive Patients With Intestinal MicrosporidiosisCompletedNCT00002191Phase 3
Sponsor listed in the registry: SmithKline Beecham · First submitted before SmithKline Beecham became part of GlaxoSmithKline
- Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML)CompletedNCT00002395Phase 2
Sponsor listed in the registry: SmithKline Beecham · First submitted before SmithKline Beecham became part of GlaxoSmithKline